Wall Street is starting to fear that shoppers might finally be hitting their limit when it comes to high prices.
TD Cowen increased its price target on Gilead Sciences (NASDAQ:GILD) shares to $100 from the previous $95, while maintaining a Buy rating on the stock. The biotech giant, currently trading near its 52 ...